ECSP066396A - Peptidos y compuestos que se unen a un receptor - Google Patents

Peptidos y compuestos que se unen a un receptor

Info

Publication number
ECSP066396A
ECSP066396A EC2006006396A ECSP066396A ECSP066396A EC SP066396 A ECSP066396 A EC SP066396A EC 2006006396 A EC2006006396 A EC 2006006396A EC SP066396 A ECSP066396 A EC SP066396A EC SP066396 A ECSP066396 A EC SP066396A
Authority
EC
Ecuador
Prior art keywords
peptides
compounds
join
receiver
tpo
Prior art date
Application number
EC2006006396A
Other languages
English (en)
Spanish (es)
Inventor
Brian R Macdonald
Jeffery Kenneth Weis
Edward John Yurkow
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066396(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of ECSP066396A publication Critical patent/ECSP066396A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/524Thrombopoietin, i.e. C-MPL ligand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
EC2006006396A 2003-08-28 2006-02-24 Peptidos y compuestos que se unen a un receptor ECSP066396A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
ECSP066396A true ECSP066396A (es) 2006-08-30

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006396A ECSP066396A (es) 2003-08-28 2006-02-24 Peptidos y compuestos que se unen a un receptor

Country Status (32)

Country Link
US (1) US7576056B2 (cg-RX-API-DMAC7.html)
EP (1) EP1675606B1 (cg-RX-API-DMAC7.html)
JP (1) JP4848277B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120078742A (cg-RX-API-DMAC7.html)
CN (2) CN1871022B (cg-RX-API-DMAC7.html)
AR (1) AR045530A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004270656B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414008B8 (cg-RX-API-DMAC7.html)
CA (1) CA2537421C (cg-RX-API-DMAC7.html)
CY (1) CY1118965T1 (cg-RX-API-DMAC7.html)
DK (1) DK1675606T3 (cg-RX-API-DMAC7.html)
EA (1) EA009286B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066396A (cg-RX-API-DMAC7.html)
ES (1) ES2626107T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170810T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032370T2 (cg-RX-API-DMAC7.html)
IL (1) IL173965A (cg-RX-API-DMAC7.html)
IS (1) IS8300A (cg-RX-API-DMAC7.html)
LT (1) LT1675606T (cg-RX-API-DMAC7.html)
ME (1) ME00313B (cg-RX-API-DMAC7.html)
MX (1) MXPA06002292A (cg-RX-API-DMAC7.html)
NO (1) NO344233B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ545455A (cg-RX-API-DMAC7.html)
PL (1) PL1675606T3 (cg-RX-API-DMAC7.html)
PT (1) PT1675606T (cg-RX-API-DMAC7.html)
RS (2) RS56387B1 (cg-RX-API-DMAC7.html)
SG (1) SG131110A1 (cg-RX-API-DMAC7.html)
SI (1) SI1675606T1 (cg-RX-API-DMAC7.html)
TW (1) TWI348375B (cg-RX-API-DMAC7.html)
UA (1) UA82710C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005023834A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602495B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
EP1124961B9 (en) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
NZ566812A (en) 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
EA009286B1 (ru) 2003-08-28 2007-12-28 Орто-Макнейл Фармасьютикал, Инк. Пептиды и соединения, которые связываются с рецептором
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
MY151332A (en) * 2006-02-14 2014-05-15 Janssen Pharmaceutica Nv Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
CA2642389C (en) * 2006-02-14 2014-05-06 Janssen Pharmaceutica N.V. Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
KR20110015448A (ko) * 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 tpo 모방 펩티드
CN103635514B (zh) 2011-06-23 2016-01-20 株式会社岛津制作所 支链型两亲性嵌段聚合物、使用其的分子聚集体及药物输送系统
US12251424B2 (en) 2017-07-26 2025-03-18 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
US20200237872A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
WO2020209920A2 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
EP3914272B1 (en) 2019-01-25 2024-03-06 Janssen Pharmaceutica NV Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
EP4408984A1 (en) 2021-10-01 2024-08-07 Janssen Pharmaceutica NV Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT644771E (pt) 1992-06-11 2002-12-31 Alkermes Inc Sistema de entrega da droga eritropoietina
EP0673387B1 (en) 1992-12-11 1999-09-22 University Of Florida Materials and methods for control of pests
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021920A1 (en) 1994-02-14 1995-08-17 Zymogenetics, Inc. Hematopoietic protein and materials and methods for making it
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0723456A1 (en) 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
SG79882A1 (en) 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
DE69503849T2 (de) 1994-03-31 1999-04-01 Amgen Inc., Thousand Oaks, Calif. Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
CA2180021A1 (en) * 1994-11-04 1996-05-17 Yoichi Kawashima Novel 1,3-dialkylurea derivatives having a hydroxyl group
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU4163196A (en) 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
JP3763846B2 (ja) 1995-04-26 2006-04-05 協和醗酵工業株式会社 新規ポリペプチド
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP1961760A3 (en) * 1995-06-07 2008-09-03 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
EP1223944B1 (en) 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietin mimetics
PL205949B1 (pl) * 2000-12-22 2010-06-30 Ipsen Mfg Ireland Ltd Sposób wytwarzania peptydu
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
NZ566812A (en) * 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
EA009286B1 (ru) 2003-08-28 2007-12-28 Орто-Макнейл Фармасьютикал, Инк. Пептиды и соединения, которые связываются с рецептором

Also Published As

Publication number Publication date
TW200517103A (en) 2005-06-01
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
IL173965A0 (en) 2006-07-05
AU2004270656A1 (en) 2005-03-17
CN102241742B (zh) 2014-04-02
US20050137133A1 (en) 2005-06-23
ZA200602495B (en) 2007-06-27
EP1675606B1 (en) 2017-04-05
NO20061346L (no) 2006-05-22
CN1871022A (zh) 2006-11-29
JP2007504132A (ja) 2007-03-01
BRPI0414008B8 (pt) 2021-05-25
TWI348375B (en) 2011-09-11
UA82710C2 (uk) 2008-05-12
SG131110A1 (en) 2007-04-26
SI1675606T1 (sl) 2017-07-31
IL173965A (en) 2015-10-29
BRPI0414008B1 (pt) 2018-05-15
MEP48508A (en) 2011-02-10
NO344233B1 (no) 2019-10-14
AU2004270656B2 (en) 2011-03-10
WO2005023834A2 (en) 2005-03-17
PL1675606T3 (pl) 2017-08-31
EA009286B1 (ru) 2007-12-28
WO2005023834A3 (en) 2005-05-06
HUE032370T2 (en) 2017-09-28
HK1096873A1 (en) 2007-06-15
EP1675606A2 (en) 2006-07-05
LT1675606T (lt) 2017-11-10
NZ545455A (en) 2009-02-28
CY1118965T1 (el) 2018-01-10
MXPA06002292A (es) 2006-09-04
US7576056B2 (en) 2009-08-18
CA2537421C (en) 2011-09-27
CN1871022B (zh) 2011-07-06
CN102241742A (zh) 2011-11-16
PT1675606T (pt) 2017-05-22
EA200600477A1 (ru) 2007-02-27
RS56387B1 (sr) 2017-12-29
IS8300A (is) 2006-02-14
KR20070017942A (ko) 2007-02-13
KR20120078742A (ko) 2012-07-10
HRP20170810T1 (hr) 2017-08-11
RS20060141A (sr) 2008-08-07
CA2537421A1 (en) 2005-03-17
ES2626107T3 (es) 2017-07-24
BRPI0414008A (pt) 2006-10-24
ME00313B (me) 2011-05-10
JP4848277B2 (ja) 2011-12-28
AR045530A1 (es) 2005-11-02
KR101183875B1 (ko) 2012-09-27

Similar Documents

Publication Publication Date Title
ECSP066396A (es) Peptidos y compuestos que se unen a un receptor
ECSP088169A (es) Peptidos y compuestos que se unen a un receptor
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
EP1630152A4 (en) CONDENSED CYCLIC COMPOUND
NL1027434A1 (nl) Bicyclische pyrazolyl- en imidazolylverbindingen, en toepassingen daarvan.
FR2884516B1 (fr) Antagonistes npy, preparation et utilisations
SMAP200800029A (it) 2-ammino-7,8-diidro-6h.pirido[4,3-d]pirimidin-5-oni
DK1749921T3 (da) Brandhæmmende, syntetisk læder
EA200601759A1 (ru) Композиции рамиприла
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
ES1057855Y (es) Escenario movil.
ES1055317Y (es) Escenario autotransportable.
DOP2002000515A (es) Lactamas como antagonista de taquiquininas.
ITBO20030177A1 (it) Calza traspirante.
FR2883012B1 (fr) Construction mobile ou fixe, pliable
ATE517821T1 (de) Behälter
UY27183A1 (es) -novedosos derivados de pirimidinona sustituidos que se combinan con receptores de integrina, su preparación y su uso.
BRPI0401530B1 (pt) fertilizadora de uso combinado.
ES1057380Y (es) Premarco.
FIU20050381U0 (fi) Kompakti konepistooli-konstruktio
ITMO20040313A1 (it) Mostarda di carpi detta fina.
ES1061217Y (es) Barrera extensible.
ES1051527Y (es) Carpeta compartimentada.
ES1058107Y (es) Casa de madera.
ES1051696Y (es) Eslinga de un solo uso, provista de precinto de seguridad.